Rigel Pharmaceuticals (RIGL) Set to Announce Quarterly Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Rigel Pharmaceuticals to post earnings of ($0.03) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Rigel Pharmaceuticals Price Performance

Shares of NASDAQ RIGL opened at $1.20 on Monday. Rigel Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $1.96. The business’s 50 day moving average price is $1.32 and its 200 day moving average price is $1.20. The firm has a market cap of $210.48 million, a P/E ratio of -8.00 and a beta of 1.06.

Analysts Set New Price Targets

A number of analysts have recently weighed in on RIGL shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 6th. B. Riley reiterated a “neutral” rating and set a $1.25 price objective on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 6th. StockNews.com cut Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 4th. Citigroup raised their target price on Rigel Pharmaceuticals from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, March 7th. Finally, Cantor Fitzgerald lifted their target price on shares of Rigel Pharmaceuticals from $2.00 to $3.00 and gave the company a “neutral” rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Rigel Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.81.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.